FDA approves crizanlizumab-tmca for sickle cell disease

On November 15, 2019, Food and Drug Administration approved crizanlizumab-tmca (ADAKVEO, Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

Read the full press release from the FDA here:

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-...

Views: 43

Reply to This

© 2021   Created by Ade Dotun.   Powered by

Badges  |  Report an Issue  |  Terms of Service